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Abstract 
ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) enzymes 
are a recently described group of metalloproteinases. The substrates degraded by 
ADAMTS-1, -4 and -5 suggests that they play a role in turnover of extracellular 
matrix in the central nervous system (CNS). ADAMTS-1 is also known to exhibit 
anti-angiogenic activity. Their main endogenous inhibitor is tissue inhibitor of 
metalloproteinases (TIMP)-3. 
 The present study was designed to investigate ADAMTS-1, -4 and -5 and TIMP-3 
expression after experimental cerebral ischaemia and to examine whether cytokines 
known to be up-regulated in stroke could alter their expression by astrocytes in vitro. 
Focal cerebral ischaemia was induced by transient middle cerebral artery occlusion in 
the rat using the filament method.  
Our results demonstrate a significant increase in expression of ADAMTS-1 and -4 in 
the occluded hemisphere but no significant change in TIMP-3. This was accompanied 
by an increase in mRNA levels for interleukin (IL)-1β, IL-1 receptor antagonist (IL-
1ra) and tumour necrosis factor (TNF). ADAMTS-4 mRNA and protein was up-
regulated by TNF in primary human astrocyte cultures. The increased ADAMTS-1 
and -4 in experimental stroke, together with no change in TIMP-3, may promote ECM 
breakdown after stroke, enabling infiltration of inflammatory cells and contribute to 
brain injury. In vitro studies suggest that the in vivo modulation of ADAMTS-1 and -4 
may be controlled in part by TNF.  
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1. Introduction 
Focal brain ischaemia induces a complex cascade of events leading to extracellular 
matrix remodelling, gliosis and neovascularisation. An increase in the expression of  
matrix metalloproteinases (MMPs) correlates to stroke pathology [6], [34], [35] and 
the use of metalloproteinase inhibitors in animal models has demonstrated effects 
such as a reduction in infarct size [13] and limitation of early blood brain barrier 
(BBB) opening [34]. ADAM-17, a member of the ADAMs family of 
metalloproteinases, is a key sheddase that releases TNF from its membrane bound 
form and is up-regulated after an ischaemic event [5]. Selective antagonists of 
ADAM-17 systemically administered in a rat model of transient middle cerebral 
artery occlusion (tMCAo) also reduced infarct size and neurological deficit [45]. 
 
A more recently described and distinct group of metalloproteinases, the ADAMTSs 
(A Disintegrin and Metalloproteinase with Thrombospondin motifs) [31], [41] are part 
of Family M12 of Clan MA in the Merops database [32] and are related to the 
ADAMs and MMPs. A phylogenetic subgroup of the ADAMTS enzymes comprising 
ADAMTS-1, -4, -5, -8, -9, and -15 possess proteoglycanase and anti-angiogenic 
activities [44]. ADAMTS-1, -4, -5 and -9 have aggrecanase activity and are 
implicated in cartilage degradation [8], [40], [43]. The ADAMTS proteoglycanases 
are inhibited by tissue inhibitor of metalloproteinases (TIMP)-3 which, like the 
ADAMTSs, is sequestered in the ECM via interactions with sulphated 
glycosaminoglycans [11], [18], [47]. ADAMTS expression has been detected in the 
CNS [1], [17], [37] and is known to be altered in disease states [10], [22], [23]. 
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The chondroitin sulphate proteoglycans (CSPGs), aggrecan, brevican, neurocan, 
phosphacan, appican and versican are expressed in the brain [3], [12], [26], [28], [46] 
and are potential substrates for ADAMTSs. These CSPGs are important to brain 
structure through maintenance of the correct hydrodynamics and in their interactions 
with other ECM components. They also contribute to disease processes and their 
synthesis is modulated by injury [14]. As a group, CSPGs are known to inhibit neurite 
outgrowth and axonal regeneration and promote neural cell death [2], [12], [15], [19], 
[39]. Therefore alterations in levels of CSPGs are relevant to neuronal survival and 
regeneration after an ischaemic event. The ADAMTSs are likely to be involved in 
modulation of CSPGs and angiogenesis in stroke pathology due to their substrate 
specificities and anti-angiogenic properties.  
 
Astrocytes are activated in response to a range of CNS pathologies including trauma, 
neurodegenerative diseases and stroke [29]. Astrocytes have many roles in cerebral 
ischaemia such as scavenging of free radicals and release of growth factors as well as 
astrogliosis which is inhibitory to axonal regeneration [25]. Recent research has 
demonstrated that the expression of CSPGs is increased by treatment of astrocytes 
with cytokines such as transforming growth factor (TGF) β1 and epidermal growth 
factor (EGF) [38]. 
 
The purpose of this study was to identify any changes in the expression of ADAMTS-
1, 4 or -5 or their endogenous inhibitor, TIMP-3, in cytokine treated astrocytes and in 
CNS tissue of rats at various time points following transient focal cerebral ischaemia, 
compared with sham operated controls. Interleukin (IL)-1β, IL-1 receptor antagonist 
(IL-1RA) and tumour necrosis factor (TNF) have been previously demonstrated to be 
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upregulated following MCAo in the rat model [4], [20] and we have therefore 
included these genes in the study to confirm the extent of ischaemia and to allow 
comparison with ADAMTS and TIMP-3 expression.  
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2. Materials and methods 
Surgical procedure  
All experiments were performed on male Sprague–Dawley rats (290–320 g; Charles 
River, U.K.) under halothane anaesthesia [Fluothane, Zeneca, U.K., 1–2% in a 
mixture of oxygen and nitrous oxide (1:2 ratio)]. Body temperature was maintained 
(37.0±0.5°C) throughout anaesthesia by means of a homeothermic blanket (Harvard 
Apparatus, U.K.). All surgical procedures were carried out in accordance with the 
United Kingdom Animals (Scientific Procedures) Act (1986). 
 
Transient focal cerebral ischaemia was induced in rats by intraluminal thread 
occlusion of the middle cerebral artery (tMCAo), as described previously [24]. The 
thread was withdrawn to allow reperfusion at 90 mins post-occlusion. Sham-operated 
animals were exposed to the same surgical procedure, with the exception that the 
thread was inserted only briefly and not to its full extent. The animals were then killed 
at different time points following tMCAo and the brains removed and frozen on dry 
ice, prior to subsequent analysis. Numbers of animals included in each group were as 
follows: 2 animals for 6 hour sham operated and 4 animals for 6 hour post tMCAo, 4 
animals for each of 24 hour sham operated and 24 hours post tMCAo, and 3 animals 
for each of 5 day sham operated and 5 days post tMCAo groups.  
 
Tissue preparation and analysis  
Brains were dissected into ipsilateral and contralateral hemispheres and each 
hemisphere was cut approximately in half again coronally. Sections of each 
hemisphere (10µm) were cut and stained with Toluidine blue to identify the ischemic 
areas by microscopical examination. 
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Astrocyte culture 
All cell culture reagents were from Invitrogen, Paisley, Scotland, unless otherwise 
stated. Human primary astrocyte cells (a kind gift from I. Romero, Milton Keynes, 
UK) were cultured in Hams F10/MEM 1:1 supplemented with 10% FCS, 1% human 
serum, 1% amphotericin B and 0.1% plasmocin (prophylactic) (Autogen Bioclear, 
Wiltshire UK). All cell culture media contained 100U/ml penicillin and 100µg/ml 
streptomycin and were maintained at 37°C in 5% CO2/95% air in a humid 
environment. Cells were trypsinised and seeded into 24-well plates at a density of 
1x105/well (1ml medium/ well) and allowed to adhere for 24 hours. The cells were 
treated with either IL-1β or TNF (recombinant cytokines; Peprotech, UK) in triplicate 
at 0, 1, 10, or 100ng/ml for 24 hours in serum-free medium. Each experiment was 
repeated 5 times.  
 
RNA/ protein extraction 
5 x 10µm sections of each quarter of brain tissue from each animal were taken and 
homogenised in 1ml of Tri-reagent (Sigma, UK), followed by vortex mixing and 
centrifugation at 12,000 x g for 15 minutes at 4°C to remove lipids. The supernatant 
was transferred to a clean microfuge tube and the RNA and protein were extracted 
following the instructions provided by the manufacturer. RNA and protein was 
extracted from triplicate wells of astrocytes into 1ml of Tri-reagent following the 
manufacturer's instructions. Samples were coded and stored at -80°C prior to use, 
when they were analysed in blinded experiments. 
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Real time PCR (qRT-PCR) 
RNA was reverse transcribed using Superscript II reverse transcriptase (Invitrogen, 
Paisley, Scotland) and the resulting cDNA was used as a template for qRT-PCR using 
the ABI PRISM 7900HT sequence detection system  and 2xSYBR Green mastermix 
(Applied Biosystems, Warrington, UK). PCR primers for ADAMTS-1, -4, -5, TIMP-3 
and GAPDH were designed using Primer Express software (Applied Biosystems) and 
obtained from MWG Biotech (Ebbersberg, Germany). In order to preclude the 
amplification of nuclear DNA, all primers crossed an exon-exon boundary. Primer 
sequences and accession numbers for ADAMTS-1, -4, -5, TIMP-3 and GAPDH are 
shown in Table 1. Sequences were confirmed as unique by a BLAST search 
(www.ncbi.nlm.nih.gov/BLAST). Each primer pair generated a single product of the 
appropriate size when visualised by melt curve analysis following qRT-PCR. Primer 
pair efficiency was determined by plotting log (cDNA dilution) against cycle 
threshold (CT), the slope of which was -3.3 +/- 0.1 for each primer pair, indicating 
maximal efficiency. Primers and FAM labelled probes were used for determination of 
IL-1β, IL-1ra and TNF expression levels (Applied Biosystems, assay numbers: 
Rn00580432-m1, Rn00573488-m1, Rn00562055 respectively). Expression of 
ADAMTS-1, -4, -5, TIMP-3, IL-1β, IL-1RA and TNF was normalised against 
expression of the housekeeping gene GAPDH. Relative mRNA levels of ADAMTS-1, 
-4, -5, TIMP-3, IL-1β, TNF, and IL-1ra were determined using the formula  2-∆CT 
where ∆CT = CT (target gene) – CT (GAPDH). Relative quantification of targets 
from cytokine stimulated cells compared to untreated cells was calculated by the 
comparative cycle threshold method, using the formula 2-∆∆CT where ∆∆CT = ∆CT 
(stimulated cells) – ∆CT (unstimulated cells) (Applied Biosystems recommendations). 
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Western blotting 
Western blot analyses of ADAMTS-1, -4 and -5 were carried out as previously 
described [10] using polyclonal antibodies for C-terminal epitopes of ADAMTS-1, -4 
and -5 (Santa Cruz Biotechnologies Inc., USA). Anti -ADAMTS-1 and ADAMTS-4 
are goat polyclonal antibodies raised against a peptide mapping near the C terminus of 
the human protein. 
Briefly, 6µg of protein per well was separated by electrophoresis on 12% NuPAGE 
gels (Invitrogen, Paisley, UK) under reducing conditions. The proteins in the gel were 
electroblotted onto a nitrocellulose membrane (Hybond-C, Amersham, UK) at 150V 
for 1 hour, Blots were blocked with 5% non-fat milk in Tris-buffered saline 
containing 0.05% Tween 20 (Sigma, UK) (TBST), washed 3 x 10 min in TBST and 
the primary antibody was added  at 1: 5000 dilution in TBST containing 5% non-fat 
milk.  The blots were incubated overnight at 4oC and washed as described above, then 
incubated with rabbit anti-goat IgG horseradish peroxidase (HRP) conjugate (Sigma, 
UK), 1:80000 in TBST for 2 hours at ambient temperature with gentle shaking. Blots 
were then washed again and developed using the ECL Plus chemiluminescence 
substrate (Amersham, UK). Peptide blocking experiments were performed on the 
antibodies using the commercially available peptides to ensure no non-specific 
binding of the secondary antibody. Detection of actin using an anti-actin antibody 
(Abcam, UK) was included as loading control in all the gels. Images were captured 
using a UVP bioimaging system (Biorad, Hertfordshire, UK). Semi-quantitation of the 
bands was carried out by densitometry. Western blot experiments were repeated three 
times. 
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Data Analysis 
Comparison of the mRNA levels of ADAMTSs, TIMP-3, IL-1β, IL-1ra and TNF 
between contralateral and ipsilateral hemispheres was performed using a paired 
Students t-test. For the cell culture experiments, statistical significance of any increase 
or decrease in expression of a particular target was determined by a one-sample t-test 
of the mean. P<0.05 was considered to be significant. All bands from western blots 
were compared to the sham operated contralateral hemisphere which was normalised 
to 1. Mean optical density values of repeated experiments were calculated and 
statistical significance of any observed differences were calculated using t- tests. 
 
Immunocytochemistry 
Primary astrocytes were plated out into chamber slides at a density of 2 x 105 cells per 
well and were allowed to adhere for 24 hours. The slides were fixed in ice-cold 
acetone for 10 minutes, air-dried and incubated in the primary rabbit polyconal 
antibody against ADAMTS -1, -4, -5  (Triple Point Biologics, USA, 1:50) or glial 
fibrillary acidic protein (GFAP) as the control (Chemicon International, UK) (1:1000) 
overnight at 4°C. Cells were then washed in PBS, and incubated with goat anti-rabbit 
IgG alexa 488 (Molecular Probes, 1:500) for 1 hour at room temperature. Non-
specific staining was determined by omission of the primary antibody and no staining 
of the tissue was observed. The nuclei were counterstained with propidium iodide 
(Dako, UK). Immunofluorescent images were captured using a Zeiss 510 confocal 
scanning laser microscope equipped with a krypton/argon laser. Fluorophores were 
excited at wavelengths of 488nm and 568nm. 
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3. Results 
ADAMTS-1, -4 -5 and TIMP-3 mRNA were all constitutively expressed in normal 
and stroke tissue (Figure 1). ADAMTS-1 and -4 was found to be constitutively 
expressed by western blotting in sham operated and MCAo tissue however using a 
number of commercially antibodies available we were unable to detect ADAMTS-5 
by western blotting (Figure 2). Basal expression of ADAMTS-4 mRNA was higher 
than that of ADAMTS-1 and -5 whereas TIMP-3 was expressed higher levels than the 
ADAMTSs.  ADAMTS-1 mRNA expression was significantly increased in the 
ipsilateral hemisphere of animals 6 and 24 hours post tMCAo (Figure 1a) compared to 
the contralateral hemisphere (mean 4.2 and 6.6 - fold increase respectively compared 
to contralateral hemisphere). The level of ADAMTS-1 mRNA expression showed no 
significant difference between hemispheres of sham operated animals and 
contralateral hemispheres of experimental animals. Protein levels of ADAMTS-1 
were unchanged in tMCAo tissue compared to sham operated at 6 and 24 hours (data 
not shown). At 5 days post tMCAo, ADAMTS-1 mRNA levels were not significantly 
different to the sham operated or contralateral hemisphere; however, protein levels of 
ADAMTS-1 were significantly increased in both the ipsilateral and contralateral 
hemispheres of tMCAo animals compared to sham operated animals (Figure 2a and 
d). ADAMTS-1 western blots showed bands at approximately 95 and 100kDa. 
 
ADAMTS-4 mRNA was also significantly increased in the ipsilateral hemisphere 
(Figure 1b), at 6 and 24 hours following tMCAo, (mean 1.8 and 2.7-fold increase 
respectively, compared to the contralateral hemisphere). ADAMTS-4 expression was 
similar in sham operated and contralateral hemispheres of experimental animals. 
Protein levels of ADAMTS-4 were unchanged in tMCAo tissue compared to sham 
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operated at 6 and 24 hours (data not shown). At 5 days post MCAo, ADAMTS-4 
mRNA levels were not significantly different to the sham operated or contralateral 
hemisphere whereas ADAMTS-4 protein levels were significantly increased in the 
ipsilateral hemisphere of the tMCAo brains compared with contralateral hemisphere 
and sham operated animals (Figure 2b and e). Bands on western blots were observed 
at approximately 51, 65-70, 85 and 100-110 kDa for the different processed forms of 
the enzyme. 
 
ADAMTS-5 mRNA showed a small increase in the ipsilateral hemisphere 6 hours 
post MCAo (1.4 fold compared to contralateral hemisphere) but was not significantly 
different from sham operated animals (Figure 1c). There was also no significant 
difference between ipsilateral and contralateral hemispheres, 24 hours post stroke or 
compared to the sham operated group at this time point. However, at 5 days post 
MCAo there was a small but significant increase in the ipsilateral hemispheres 
compared to the sham operated animals but no difference between ipsilateral and 
contralateral hemispheres (Figure 1c).  
 
CNS TIMP-3 expression levels were not significantly different between MCAo and 
control animals at any of the time points tested (Figure 1d).  
 
IL-1β, IL-1RA and TNF have all previously been shown to be increased in stroke [4], 
[16], [20]. We therefore examined the expression of these genes as evidence of the 
ischaemic event. Increased expression of IL-1β, (mean 34-fold increase) IL-1RA 
(mean 15-fold increase) and TNF (mean 3-fold increase) was observed in the 
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ipsilateral tissue compared to contralateral stroke tissue at 24 hours after tMCAo 
(Figure 3). 
 
Using immunocytochemistry, primary human astrocytes in vitro were shown to 
constitutively express ADAMTS-1, -4 and -5 proteins. ADAMTS-1 appeared to show 
the highest expression levels and ADAMTS-4 and -5 staining was much weaker 
(Figure 4). Real time PCR experiments showed that IL-1β treatment did not 
significantly alter expression levels of ADAMTS-1, -5 or TIMP-3 in astrocytes, 
although significantly increased ADAMTS-4 expression at 1ng/ml (mean of 3.5 fold 
increase) (Figure 5a). No significant changes were seen at 10 and 100ng/ml IL-1β. 
Western blotting experiments showed no significant differences in ADAMTS-1, -4, -5 
or TIMP-3 between control and IL-1β stimulated cells (data not shown). ADAMTS-1 
(mean of 3-fold increase at 100ng/ml TNF) and ADAMTS-4 (mean of 9-fold increase 
at 100ng/ml TNF) expression levels however, were significantly increased following 
TNF treatment, with no effect on the levels of ADAMTS-5 or TIMP-3 (Figure 5b). 
The increase in ADAMTS-4 mRNA in TNF treated astrocytes was mirrored in 
western blotting experiments, although a significant increase in ADAMTS-1 was not 
observed at the protein level. ADAMTS-5 protein was significantly increased 
following TNF stimulation and TIMP-3 levels remained unchanged (Figures 6 and 7). 
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4. Discussion 
CNS trauma and stroke lead to a reactive gliosis characterised by increased GFAP 
expression and hypertrophy of astrocytes [29]. This is accompanied by alterations to 
many brain ECM components including an increase in CSPGs [9], [38]. ADAMTSs 
specifically degrade CSPGs and an increase in degradation of ECM components may 
aid recovery by removal of the CSPGs that are inhibitory to neurite outgrowth. 
Conversely, increased ADAMTS mediated CSPG degradation may potentiate brain 
injury and enable infiltration of inflammatory cells [14], [33]. 
These results demonstrate that ADAMTS-1 and -4 mRNA expression is significantly 
increased in the ipsilateral hemisphere compared to either the contralateral 
hemisphere or to brain tissue from sham operated rats at 6 hours and is further 
increased at 24 hours post tMCAo. This increase then returns to control levels by 5 
days post tMCAo. TIMP-3 mRNA expression levels remained unchanged at each of 
the time points tested. Protein levels of ADAMTS-1 and -4 were also upregulated in 
tMCAo although this was only observed at 5 days post procedure. Interestingly, 
ADAMTS-1 protein was upregulated in both hemispheres of the tMCAo brains at 5 
days post procedure whereas ADAMTS-4 was only upregulated in the ipsilateral 
hemisphere. This indicates that there may be different control mechanisms between 
different ADAMTSs.  The unchanged TIMP-3 levels following stroke is in contrast to 
experimental autoimmune encephalomyelitis where we demonstrated a significant 
decrease in TIMP-3 mRNA at the peak of the disease [30].  
 
IL-1β has previously been shown to increase ADAMTS expression in other systems 
such as a murine colon carcinoma cell line [17] and in human tendon cells [42]. The 
increase in cytokine expression following stroke has previously been documented by 
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others [4], [20], [27], [36]. Levels of IL-1β mRNA were 34 times higher in ipsilateral 
hemisphere compared to the contralateral hemisphere in the present study. Clausen et 
al, [7] have also reported a similar fold increase in IL-1β mRNA levels 24 hours after 
MCAo in a mouse model and further demonstrated a dramatic decline in the relative 
levels of IL-1β mRNA in the ischaemic hemisphere after 5 days post MCAo. Our 
results also demonstrated a 15-fold increase in IL-1RA mRNA levels in ipsilateral 
compared to contralateral stroke tissue which was previously demonstrated to be 
increased by Legos et al, [20] following focal ischaemia in the rat. IL-1β has been 
shown to play an important role in ischaemic brain injury, where there is a reduction 
in ischemic cell death in rodents when IL-1ra is administered [24]. We have also 
shown a significant (3-fold) increase in TNF in ipsilateral tissue compared to 
contralateral, 24 hours after MCAo.  
 
We have demonstrated the expression of ADAMTS-1, -4 and -5 by primary human 
astrocytes in vitro and have shown an increase in ADAMTS-4 mRNA and protein 
expression in response to TNF treatment. In contrast, IL-1 did not significantly alter 
expression of ADAMTS-1 mRNA or protein by astrocytes and only increased 
ADAMTS-4 mRNA expression at 1ng/ml, the lowest concentration used. IL-1 has 
been shown to increase ADAMTS-1 expression in other systems [17], suggesting a 
differential cell type specific response. These findings support evidence for TNF 
induced up-regulation of ADAMTS-4 expression by astrocytes in vivo following 
stroke.  
It remains to be determined whether the increase in ADAMTS-1 and -4 is beneficial 
or detrimental to the process of regeneration of function following stroke but as this 
becomes more clearly defined, new therapeutic targets may emerge. 
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Figure legends 
 
Figure 1. Relative mRNA expression of ADAMTS-1 (a), ADAMTS-4 (b), 
ADAMTS-5 (c) and TIMP-3 (d) at 6, 24 and 120 hours post tMCAo and in sham 
operated rat brain measured by real time PCR. Data are represented as mean +/- 
standard error of the mean from contralateral (CL), ipsilateral (IL) and sham operated 
hemispheres. * denotes significant increase (P<0.05) ** (P<0.01) between data using 
a paired T test. 
 
Figure 2.  Protein samples from rat brain (6µg/well) were analysed using ADAMTS-1 
and -4 antibodies. A representative western blot of sham operated rat brain and 
MCAo, 5 days post procedure for ADAMTS-1 (a) and -4 (b). Blots show two animals 
for each contralateral (CL) and ipsilateral (IL) hemispheres in sham operated and 
MCAo brain. The actin control for the representative samples is also shown (c). 
Densitometric analysis is shown for the mean of 3 animals in each group +/- SEM 
(pooled analysis of molecular weight bands) for ADAMTS-1 (d) and -4 (e) 
expression. * represents a significant increase in expression P<0.05.  
 
Figure 3. Relative mRNA expression of IL-1β (a), IL-1RA (b) and TNF (c) in sham 
operated rat brain and 24 hours after tMCAo measured by real time PCR. Data are 
represented as mean +/- standard error of the mean of 4 repeat experiments. CNS 
tissue from sham operated rats is numbered 1-4 and tissue from tMCAo, numbered 5-
8, left side (L) and right (occluded) side (R). * denotes significant increase (P<0.05) 
compared to contralateral hemisphere using a paired T test. 
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Figure 4 Immunocytochemistry on primary human astrocytes. Cells were plated into 
chamber slides at a density of 2x105 cells per well and allowed to adhere for 24 hours. 
Cells were incubated with primary antibodies against GFAP (a), ADAMTS-1 (b), 
ADAMTS-4 (c) or ADAMTS-5 (d) followed by goat anti-rabbit IgG alexa 488 
secondary antibody (green). Nuclei were counterstained using propidium Iodide (red). 
Bar represents 50µM. 
 
Figure 5 mRNA expression of ADAMTS-1, -4, -5 and TIMP-3 in primary human 
astrocytes by real time PCR following treatment with either IL-1β (a) or TNF (b) for 
24 hours. Data is expressed as fold increase compared to control unstimulated mRNA 
levels. * denotes significant increase (P<0.05) between control and cytokine treated 
cells using a one sample t test. 
 
Figure 6 Protein expression of ADAMTS-1 (a), -4 (b), -5 (c) and TIMP-3 (d) in TNF 
stimulated primary human astrocytes by western blotting. A representative blot is 
shown for each. Lanes 1: Control, 2: TNF 1ng/ml, 3: TNF 10 ng/ml, 4: TNF 
100ng/ml. 
 
Figure 7 Densitometry on western blots from TNF stimulated primary human 
astrocytes for ADAMTS-1 (a), -4 (b), -5 (c) and TIMP-3 (d). * indicates significant 
difference compared to control (P<0.05). 
  
 
 
 
 18 
 
References 
 
[1] Abbaszzade, I., Liu, R.Q., Yang, F., Rosenfield, S.A., Ross, O.H., Link, J.R., Ellis, 
D.M., Tortorella, M.D., Pratta, M.A., Hollis, J.M., Wynn, R., Duke, J.L., Hillman, 
M.C., Murphy, K., Wiswall, B.H., Copeland, R.A., Decicco, R.I., Bruckner, R., 
Nagase, H., Itoh, Y., Newton, R.C., Magolda, R.L., Trzaskos, J.M., Arner, E.C. and 
Burn, T.C. Cloning and characterisation of ADAMTS-11, an aggrecanase from the 
ADAMTS family.  J Biol Chem. 274 (1999) 23443-23450. 
 
 
[2] Asher, R.A., Morgenstern, D.A., Shearer, M.C., Adcock, K.H., Pesheva, P., and 
Fawcett,J.W. Versican is upregulated in CNS injury and is a product of 
oligodendrocyte lineage cells. J Neurosci.. 22 (2002) 2225-2236. 
 
[3] Bandtlow, C.E. and Zimmermann, D.R. Proteoglycans in the developing brain: 
new conceptual insights for old proteins. Physiol Rev. 80 (2000) 1267-1290.  
 
[4] Buttini M, Appel K, Sauter A, Gebicke-Haerter PJ, Bo HW. Expression of tumour 
necrosis factor alpha after focal cerebral ischaemia in the rat. Neuroscience. 71 (1996) 
1-16. 
 
[5] Cardenas A, Moro MA, Leza JC, O'Shea E, Davalos A, Castillo J, Lorenzo P, 
Lizasoain I.. Upregulation of TACE/ADAM17 after ischemic preconditioning is 
involved in brain tolerance.  J Cereb Blood Flow Metab. 22 (2002) 1297-302.  
 19 
 
[6] Clark AW, Krekoski CA, Bou S-S, Chapman KR, Edwards DR. Increased 
gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal 
ischemia. Neuroscience letts 238 (1997) 53-56 
 
[7] Clausen BH, Lambertsen KL, Meldgaard M and Finsen B. A quantitative in situ 
hybridization and polymerase chain reaction study of microglial-macrophage 
expression of interleukin-1beta mRNA following permanent middle cerebral 
occlusion in mice. Neuroscience 132 (200) 5879-892. 
 
[8] Collins-Racie LA, Flannery CR, Zeng W, Corcoran C, Annis-Freeman B, 
Agostino MJ, Arai M, DiBlasio-Smith E, Dorner AJ, Georgiadis KE, Jin M, Tan XY, 
Morris EA, LaVallie ER.. ADAMTS-8 exhibits aggrecanase activity and is expressed 
in human articular cartilage. Matrix Biol. 23 (2004) 219-30.  
 
[9] Eddleston M, Mucke L.. Molecular profile of reactive astrocytes- implications for 
their role in neurologic disease. Neuroscience. 54 (1993)15-36.  
 
[10]  Haddock, G., Cross, AK., Surr, J., Plumb, J., Buttle, DJ., Bunning, RAD., 
Woodroofe, MN. Expression of ADAMTS -1, -4, -5 and TIMP-3 in normal and 
multiple sclerosis CNS white matter. Multiple Sclerosis. 2006, in press. 
 
[11] Hashimoto, G., Aoki, T.,  Nakamura, H.,  Tanzawa, K. and Okada, Y. Inhibition 
of ADAMTS4 (aggrecanase-1) by tissue inhibitors of metalloproteinases (TIMP-1, 2, 
3 and 4). FEBS Lett. 494 (2001)192-195. 
 20 
 
[12] Inatani, M., Honjo, M., Otori, Y., Oohira, A., Kido, N., Tano, Y., Honda, Y. and 
Tanihara H. Inhibitory effects of neurocan and phosphacan on neurite outgrowth from 
retinal ganglion cells in culture. Invest. Ophthalmol .Vis .Sci. 42 (2001)1930-1938. 
 
[13] Jiang X, Namura S, Nagata I. Matrix metalloproteinase inhibitor KB-R7785 
attenuates brain damage resulting from permanent focal cerebral ischemia in mice. 
Neurosci Lett. 305 (2001) 41-44.  
 
 
[14] Jones, L.L.,  Margolis, R.U. and Tuszynski, M.H.. The chondroitin sulphate 
proteoglycans neurocan, brevican, phosphacan and versican are differentially 
regulated following spinal cord injury. Exp. Neurol. 182 (2003) 399-411. 
 
[15] Krekoski, C.A., Neubauer, D., Zuo, J.,  Muir, D.. Axonal regeneration into 
acellular nerve grafts is enhanced by degradation of chondroitin sulfate proteoglycan. 
J. Neurosci. 21 (2001) 6206-6213. 
 
[16] Krupinski J,  Kumar P, Kumar S and Kaluza J. Increased expression of TGF-beta 
1 in brain tissue after ischemic stroke in humans. Stroke. 27 (1996) 852-857. 
 
[17] Kuno, K., Kanada, N., Nakashima, E., Fujiki, F., Ichimura, F. and Matsushima, 
K.. Molecular cloning of a gene encoding a new type of metalloproteinase-disintegrin 
family protein with thrombospondin motifs as an inflammation associated gene.  J 
Biol Chem. 272 (1997)556-562. 
 21 
 
[18] Kuno, K. and  Matsushima, K.. ADAMTS-1 protein anchors at the extracellular 
matrix through the thrombospondin type 1 motifs and its spacing region. J.Biol.Chem. 
273 (1998) 13912-13917. 
 
[19]  Kurazono, S., Okamoto, M., Mori, S. and Matsui, H.. Recombinant core protein 
fragment of phosphocan, a brain specific chondroitin sulfate proteoglycan, promote 
excitotoxic cell death of cultured rat hippocampal neurons. Neurosci. Lett. 304 (2001) 
169-172. 
 
[20] Legos JJ, Whitmore RG, Erhardt JA, Parsons AA, Tuma RF and Barone FC. 
Quantitative changes in interleukin proteins following focal stroke in the rat. 
Neurosci. Lett. 282 (2000) 189-192. 
 
[21] Luque A., Carpizo DR., Iruela-Arispe ML.. ADAMTS-1/ METH1 inhibits 
endothelial cell proliferation by direct binding and sequestration of VEGF153. J Biol 
Chem. 278 (2003) 23656-23665. 
 
[22] Medina-Flores R, Wang G, Bissel SJ, Murphey-Corb M, Wiley CA. Destruction 
of extracellular matrix proteoglycans is pervasive in simian retroviral neuroinfection. 
Neurobiol Dis. (2004) 16(3):604-16.  
 
[23] Miguel RF, Pollak A, Lubec G.. Metalloproteinase ADAMTS-1 but not 
ADAMTS-5 is manifold overexpressed in neurodegenerative disorders as Down 
syndrome, Alzheimer's and Pick's disease. Brain Res Mol Brain Res. 133 (2005) 1-5.  
 22 
 
[24] Mulcahy N.J., Ross J., Rothwell N.J. and Loddick S.A.  . Delayed administration 
of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the 
rat. Br J Pharmacol. 2003 140 (2003) 471-476. 
 
[25] Nedergaard M and Dirnagl U,. Role of glial cells in cerebral ischemia. Glia 50 
(2005) 281-286. 
 
 [26] Novak, U. and Kaye, A.H.. Extracellular matrix and the brain: components and 
function. J Clin Neurosci . 7 (2000) 280-290. 
 
[27] Ohtaki H, Yin L, Nakamachi T, Dohi K, Kudo Y, Makino R and Shioda S.  
Expression of tumour necrosis factor a in nerve fibres and oligodendrocytes after 
transient focal ischaemia in mice. Neuroscience Letts. 368 (2004) 162-166. 
 
 
[28] Pangalos, MN., Shioi, J., Efthimiopoulos, S., Wu, A. and Robakis, NK.. 
Characterization of appican, the chondroitin sulfate proteoglycan form of the 
Alzheimer amyloid precursor protein. Neurodegeneration 5 (1996) 445-451. 
 
[29] Pekny M. and Nilsson M.. Astrocyte activation and reactive gliosis. Glia. 50 
(2005) 427-434. 
 
[30] Plumb  J, Cross AK, Surr J, Haddock G, Smith T, Bunning RAD and Woodroofe 
MN. ADAM-17 and TIMP-3 protein and mRNA expression in spinal cord white 
 23 
matter of rats with acute experimental autoimmune encephalomyelitis. J 
Neuroimmunol. 164 (2005) 1-9. 
 
[31] Porter, S., Clark, IM., Kevorkian, L and Edwards, D.R.. The ADAMTS 
metalloproteinases. Biochem J. 386 (2005) 15-27. 
 
[32] Rawlings,N.D., O'Brien,E.A. and Barrett,A.J. MEROPS the protease database. 
Nucleic Acids Res. 30 (2002) 343-346. 
 
[33] Rhodes KE. and Fawcett JW.. Chondroitin sulphate proteoglycans: preventing 
plasticity or protecting the CNS? J Anat. 204 (2004) 33-48. 
 
[34] Rosenberg GA, Estrada EY, Dencoff JE.  . Matrix metalloproteinases and TIMPs 
are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 
29 (1998) 2189-95.  
 
[35] Rosenberg G.A. Matrix metalloproteinases in neuroinflammation. Glia 39 (2002) 
.279-291. 
 
[36] Rothwell N.. Interleukin-1 and neuronal injury: mechanisms, modification and 
therapeutic potential. Brain Behaviour and Immunity. 17 (2003) 152-157. 
 
[37] Satoh K., Suzuki N. and Yokota H.. ADAMTS-4 (a disintegrin and 
metalloproteinase with thrombospondin motifs) is transcriptionally induced in beta-
amyloid treated astrocytes.  Neurosci Letts. 289 (2000) 177-180. 
 24 
 
[38] Smith GM and Strunz C. Growth factor and cytokine regulation of chondroitin 
sulphate proteoglycans by astrocytes. Glia. 2005 
 
[39] Sobel, R.A. and Ahmed, A.S.. White matter extracellular matrix chondroitin 
sulfate/dermatan sulfate proteoglycans in multiple sclerosis. J. Neuropathol. Exp. 
Neurol., 60 (2001) 1198-1207. 
 
[40] Somerville, R.P.T.,  Longpre, J.M., Jungers, K.A., Engle, J.M., Ross, M., 
Evanko, S., Wight, T.N., Leduc, R. and Apte, SS. Characterization of ADAMTS-9 
and ADAMTS-20 as a distinct ADAMTS subfamily related to Caenorhabditis elegans 
GON-1. J Biol Chem. 278 (2003) .9503-9513. 
 
[41] Tang, B.L. ADAMTS: a novel family of extracellular matrix proteases. Int J 
Biochem Cell Biol.  33 (2001) 33-44. 
 
[42] Tsuzaki, M., Guyton, G., Garrett, W., Archambault, J.M., Herzog, W., 
Almekinders, L., Bynum, D., Yang, X., Banes, A.J.. IL-1 beta induces COX2, MMP-
1, -3 and 13, ADAMTS-4, IL-1 beta and IL-6 in human tendon cells.  J. Orthop. Res. 
21 (2003) 256-264. 
 
[43] Vankemmelbeke, M.N., Jones, G.C., Fowles, C.  Ilic, M.Z., Handley, C.J., Day, 
A.J., Knight, C.G., Mort, J.S. and  Buttle, D.J. 2003. Selective inhibition of 
ADAMTS-1, -4 and -5 by catechin gallate esters. Eur J Biochem 270: 2394-2403. 
 
 25 
[44] Vazquez, F., Hastings, G., Ortega, M-A., Lane, T.F., Oikemus, S., Lombardo, M. 
and  Iruela-Arispe, M.L. 1999. METH-1, a human ortholog of ADAMTS-1, and 
METH-2 are members of a new family of proteins with angio-inhibitory activity. J 
Biol Chem 274: 23349-23357. 
 
[45]Wang X, Feuerstein GZ, Xu L, Wang H, Schumacher WA, Ogletree ML, Taub R, 
Duan JJ, Decicco CP, Liu RQ. 2004 Inhibition of tumor necrosis factor-alpha-
converting enzyme by a selective antagonist protects brain from focal ischemic injury 
in rats. Mol Pharmacol. 65: 890-896.  
 
 
[46] Yamaguchi, Y. 2000. Lecticans: organizers of the brain extracellular matrix. Cell 
Mol Life Sci 57: 276-289. 
 
 
[47] Yu, W-H., Yu, S.C., Meng, Q., Brew, K. and  Woessner, J.F. 2000. TIMP-3 
binds to sulfated glycosaminoglycans of the extracellular matrix. J. Biol. Chem. 275: 
31226-31232. 
 
 
 
 
 
 
 
 26 
 
 
 
 
 
